Clinical Trial

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Name: Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases — clinical trial record (NCT07343479)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a prospective, open-label, multi-center, single-arm clinical trial

Trial Details

NCT Number	NCT07343479
Lead Sponsor	Zhejiang Cancer Hospital Collaborators: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Conditions	NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Gene Mutations, Brain Metastasis
Enrollment	45 participants
Start Date	2026-05-01
Primary Completion	2027-06-20 (estimated)
Study Completion	2029-12-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-15